RT Journal Article
SR Electronic
T1 Heart Rate n-Variability (HRnV) Measures for Prediction of Mortality in Sepsis Patients Presenting at the Emergency Department
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.26.20248866
DO 10.1101/2020.12.26.20248866
A1 Liu, Nan
A1 Chee, Marcel Lucas
A1 Qi Foo, Mabel Zhi
A1 Pong, Jeremy Zhenwen
A1 Guo, Dagang
A1 Koh, Zhi Xiong
A1 Wah Ho, Andrew Fu
A1 Niu, Chenglin
A1 Chong, Shu-Ling
A1 Hock Ong, Marcus Eng
YR 2021
UL http://medrxiv.org/content/early/2021/01/02/2020.12.26.20248866.abstract
AB Background Sepsis is a potentially life threatening condition that requires prompt recognition and treatment for optimal outcomes. There is little consensus on an objective way to assess for sepsis severity and risk for mortality. In recent years, heart rate variability (HRV), a measure of the cardiac autonomic regulation derived from short electrocardiogram tracings, has been found to correlate with sepsis mortality, and its use as a prognostic variable and for risk stratification has been promising. In this paper, we present using novel heart rate n-variability (HRnV) measures for sepsis mortality risk prediction and compare against current mortality prediction scores.Methods This study was a retrospective cohort study on a convenience sample of patients presenting to the emergency department (ED) of Singapore General Hospital between September 2014 to April 2017. Patients were included in the study if they were above 21 years old, were suspected to have sepsis by their attending physician, triaged as emergency or urgent cases, and if they met two or more of the Systemic Inflammatory Response Syndrome (SIRS) criteria. Demographic and clinical variables were obtained from the electronic medical records, and HRV and novel HRnV parameters were calculated from five minute ECG tracings. Univariable analysis was conducted on variables obtained, with the primary outcome being 30-day in-hospital mortality (IHM). Variables selected through univariable analysis and stepwise selection were included in a multivariable logistic regression model, the results of which were presented using receiver operating curve (ROC) analysis.Results Of 342 patients included for final analysis, 66 (19%) met with the primary outcome. On univariable analysis, 85 out of 142 analysed HRV and HRnV parameters showed statistical difference between groups. The final multivariable logistic regression model comprised of 21 variables including four vital signs, two HRV parameters, and 15 HRnV parameters. The area under the curve (AUC) of the model was 0.86 (95% confidence interval 0.81-0.90), outperforming several established clinical scores.Conclusion The use of novel HRnV measures can provide adequate power to predictive models in the risk stratification of patients presenting to the ED with sepsis. When included in a multivariable logistic regression model, the HRnV-based model outperformed traditional risk stratification scoring systems. The HRnV measures may have potential to allow for a rapid, objective, and accurate means of patient risk stratification for sepsis severity and mortality.Competing Interest StatementNL and MEHO are the inventors on a patent [US10299689B2] that is issued by the United States Patent and Trademark Office relevant to the material in this paper. NL, DG, ZXK, and MEHO own stock in TIIM Healthcare that produces a product relevant to the subject material. MLC, MZQF, JZP, AFWH, CN, and SLC report no conflict of interest.Funding StatementThis work was supported by the Duke-NUS Signature Research Programme funded by the Ministry of Health, Singapore. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the SingHealth Centralized Institutional Review Board (CIRB Ref No.: 2016/2858), with requirement for patient consent waived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.